CSF tau protein: A new prognostic marker for Guillain-Barré syndrome

Neurology

Volumn 67, Issue 8, 2006, Pages 1470-1472

  Jin, K ^a,b   Takeda, A ^c   Shiga, Y ^c   Sato, S ^a   Ohnuma, A ^a   Nomura, H ^a   Arai, H ^c   Kusunoki, S ^d   Ikeda, M ^e   Itoyama, Y ^c  

^a KOHNAN HOSPITAL   (Japan)

^b National Hospital Organization Iwate Hospital   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; LABORATORY TEST; LOGISTIC REGRESSION ANALYSIS; MALE; NERVE FIBER DEGENERATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SCORING SYSTEM;

ADULT; AGED; ANTIBODIES; AXONS; BIOLOGICAL MARKERS; ELECTRODIAGNOSIS; FEMALE; GLYCOLIPIDS; GUILLAIN-BARRE SYNDROME; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RESPIRATION, ARTIFICIAL; TAU PROTEINS;

EID: 33750376704     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000240119.29939.c7     Document Type: Article

References (10)

1. The Italian Guillain-Barré syndrome Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. Brain 1996;119:2053-2061.
2. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of τ proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-1834.
3. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995;38:649-652.
4. Süssmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 2001;300:95-98.
5. Couchie D, Mavilia C, Georgieff IS, et al. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc Natl Acad Sci USA 1992;89:4378-4381.
6. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27(suppl):S21-24.
7. Hughes RAC, Newsom-Davis JM, Perkins GD. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.
8. Hadden RDM, Cornblath DR, Hughes RAC, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998;44:780-788.
9. Kusunoki S, Chiba A, Kon K, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol 1994;35:570-576.
10. Johnson GV, Seubert P, Cox TM, et al. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J Neurochem 1997;68:430-433.